Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 31;15(1):297. doi: 10.3390/cancers15010297

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Survival analysis of progression-free survival in all early-stage prostate cancer patients. (A) The median PFS is 15 months in all mHSPC patients. (B) Stratified to ¹⁷⁷Lu-PSMA (n = 18) vs. tandem of ¹⁷⁷Lu-PSMA and ²²⁵Ac-PSMA (n = 2), the median PFS was 12 and 17 months respectively. mHSPC = metastatic hormone-sensitive prostate cancer; PFS = progression-free survival; PSA = prostate specific antigen; PSMA = prostate specific membrane antigen.